68Ga-前列腺特异性膜抗原PET/CT在三阴性乳腺癌中的应用
本文报告一例30岁女性双侧三阴性乳腺癌患者,经双侧乳房切除术、化疗和放疗后出现左侧胸壁和肝脏复发,复发灶仍为三阴性。因已知预后差且治疗选择非常有限,在标准治疗耗尽后行68Ga-PSMA PET/CT扫描,以探索基于PSMA治疗作为未来选择的可能性。
要点
- 乳腺癌可表达前列腺特异性膜抗原(PSMA)。
- 三阴性乳腺癌复发后标准治疗选择有限。
- 68Ga-PSMA PET/CT可用于探索PSMA靶向治疗的可能性。
核心结论
- 在标准治疗耗尽后行68Ga-PSMA PET/CT扫描,以探索基于PSMA治疗作为未来选择的可能性。
研究设计与样本
- 病例报告:一例30岁女性双侧三阴性乳腺癌患者。
主要发现
- 患者经双侧乳房切除术、化疗和放疗后出现左侧胸壁和肝脏复发。
- 复发灶仍为三阴性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prostate-specific membrane antigen (PSMA) is a transmembrane protein with elevated expression in prostate cancer cells. Breast cancer also shows PSMA expression. We present the case of a 30-year-old woman with triple-negative bilateral breast carcinoma who underwent bilateral mastectomy, chemotherapy, and radiotherapy. She developed a left chest wall and liver recurrence after primary therapy. Her recurrent disease was also triple-negative. In view of the known poor prognosis and very limited therapeutic options, we performed Ga-PSMA PET/CT scan to explore the possibility of PSMA-based therapy as a future option after exhausting standard-of-care treatments.
引用
- Passah A, Arora S, Damle NA, et al. 68Ga-Prostate-Specific Membrane Antigen PET/CT in Triple-Negative Breast Cancer. Clin Nucl Med. 2018. PMID: 29578872. doi:10.1097/RLU.0000000000002071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。